23 results on '"Uggeri, M."'
Search Results
2. Rescuing defective CFTR applying a drug repositioning strategy based on computational studies, surface plasmon resonance and cell-based assays
- Author
-
D’Ursi, P., Orro, A., Urbinati, C., Uggeri, M., Paiardi, G., Millo, E., Milanesi, L., Pedemonte, N., Fossa, P., and Rusnati, M.
- Subjects
CFTR, computational chemistry, SPR ,SPR ,CFTR ,computational chemistry - Published
- 2020
3. Exploitation of a novel biosensor based on the full-length human F508de1-CFTR with computational studies, biochemical and biological assays for the characterization of a new Lumacaftor/Tezacaftor analogue
- Author
-
D'Ursi P., Uggeri M., Urbinati C., Millo E., Paiardi G., Milanesi L., Ford R. C., Clews J., Meng X., Bergese P., Ridolfi A., Pedemonte N., Fossa P., Orro A., and Rusnati M.
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Computational chemistry ,Surface plasmon resonance ,technology, industry, and agriculture ,respiratory system ,CFTR ,Molecular dynamics ,digestive system diseases ,Biosensor ,Cystic fibrosis ,respiratory tract diseases - Abstract
Cystic fibrosis (CF) is mainly caused by the mutation F508del of the cystic fibrosis transmembrane conductance regulator (CFTR) that is thus retained in the endoplasmic reticulum and degraded. New drugs able to rescue F508del-CFTR trafficking and activity are eagerly awaited, a goal that requires the availability of computational and experimental models closely resembling the F508del-CFTR structure and environment in vivo. Here we describe the development of a biosensor based on F508del-CFTR in a lipid environment that proved to be endowed with a wider analytical potential in respect to the previous CFTR-based biosensors. Integrated with an appropriate computational model of the whole human F508del-CFTR in lipid environment and CFTR stability and functional assays, the new biosensor allowed the identification and characterization at the molecular level of the binding modes of some known F508del-CFTR-rescuing drugs and of a new aminoarylthiazole-Lumacaftor/Tezacaftor hybrid derivative endowed with promising F508del-CFTR-binding and rescuing activity.
- Published
- 2019
- Full Text
- View/download PDF
4. Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action
- Author
-
Colombatti, R, Martella, M, Cattaneo, L, Viola, G, Cappellari, A, Bergamo, C, Azzena, S, Schiavon, S, Baraldi, E, Dalla Barba, B, Trafojer, U, Corti, P, Uggeri, M, Tagliabue, P, Zorloni, C, Bracchi, M, Biondi, A, Basso, G, Masera, N, Sainati, L, Tagliabue, PE, BRACCHI, MICHELA FAUSTA, Colombatti, R, Martella, M, Cattaneo, L, Viola, G, Cappellari, A, Bergamo, C, Azzena, S, Schiavon, S, Baraldi, E, Dalla Barba, B, Trafojer, U, Corti, P, Uggeri, M, Tagliabue, P, Zorloni, C, Bracchi, M, Biondi, A, Basso, G, Masera, N, Sainati, L, Tagliabue, PE, and BRACCHI, MICHELA FAUSTA
- Abstract
Background: Sickle cell disease (SCD) is a chronic multisystem disorder requiring comprehensive care that includes newborn screening (NBS) as the first step of care. Italy still lacks a national SCD NBS program and policy on blood disorders. Pilot single-center screening programs and a regional targeted screening have been implemented so far, but more evidence is needed in order to impact health policies. Population and methods: NBS was offered to parents of newborns in gynecology clinics in Padova and Monza, tertiary care university hospitals in northern Italy. High-performance liquid chromatography (HPLC) was performed as the first test on samples collected on Guthrie cards. Molecular analysis of the beta-globin gene was performed on positive samples. Results: A total of 5466 newborns were enrolled; for 5439, informed consents were obtained. A similar family origin was seen in the two centers (65% Italians, 9% mixed couples, 26% immigrants). Compared with SCD NBS programs in the United States and Europe, our results show a similar incidence of SCD patients and carriers. All SCD patients had a Sub-Saharan family background; HbS carriers were 15% Caucasians (Italian, Albanians) and 10% from other areas (North Africa–India–South America); carriers of other hemoglobin variants were mainly (47%) from other areas. Conclusions: Our results demonstrate the feasibility of a multicentric NBS program for SCD, give information on HbS epidemiology in two Northern Italian Areas, and support previous European recommendation for a universal NBS program for SCD in Italy: a high incidence of patients and carriers has been detected, with a high percentage of Caucasian carriers, impossible to identify in a targeted NBS.
- Published
- 2019
5. RET receptor expression in thyroid follicular epithelial cell-derived tumors
- Author
-
Bunone G, Uggeri M, Mondellini P, Marco Alessandro Pierotti, and Bongarzone I
- Subjects
Platelet-Derived Growth Factor ,Glial Cell Line-Derived Neurotrophic Factor Receptors ,Base Sequence ,Reverse Transcriptase Polymerase Chain Reaction ,Blotting, Western ,Molecular Sequence Data ,Proto-Oncogene Proteins c-ret ,Receptor Protein-Tyrosine Kinases ,Nerve Tissue Proteins ,Sequence Analysis, DNA ,Precipitin Tests ,Proto-Oncogene Mas ,Adenocarcinoma, Papillary ,Proto-Oncogene Proteins ,Adenocarcinoma, Follicular ,Tumor Cells, Cultured ,Drosophila Proteins ,Humans ,Glial Cell Line-Derived Neurotrophic Factor ,Nerve Growth Factors ,Thyroid Neoplasms ,Phosphorylation - Abstract
The RET proto-oncogene encodes a receptor tyrosine kinase for transforming growth factor-beta-related neurotrophic factors, which include GDNF and neurturin. The expression of RET proto-oncogene was detected in several tissues, such as spleen, thymus, lymph nodes, salivary gland, and spinal cord, and in several neural crest-derived cell lines. RET expression in the thyroid gland was reported to be restricted to neural crest-derived C cells. The presence of RET mRNA or protein has not yet been reported in thyroid follicular cells. We previously demonstrated the expression of oncogenic rearranged versions of RET in papillary thyroid carcinomas: tumors derived from thyroid follicular cells. To assess the expression of the normal RET proto-oncogene in follicular cells, we analyzed its expression in a panel of neoplasias originating from thyroid follicular epithelial cells: papillary carcinomas and both follicular adenomas and carcinomas. We also demonstrated the presence of RET normal transcripts in two follicular thyroid carcinoma lymph node metastases. Moreover, we found the presence of the RET/ELE1 transcript, the reciprocal complementary form of the oncogenic fusion transcript ELE1/RET, in a papillary thyroid carcinoma specimen expressing the RET/PTC3 oncogene, thus demonstrating that the RET promoter is active in those cells after rearrangement. Finally, we show that in a papillary carcinoma-derived cell line expressing the proto-RET receptor and the related GFRalpha2 co-receptor, GDNF treatment induced RET tyrosine phosphorylation and subsequent signal transduction pathway, indicating that RET could be active in thyroid follicular cells.
- Published
- 2000
6. A604 HALOTHANE ATTENUATES BOTH RECEPTOR AND NON RECEPTOR MEDIATED EDRF PRODUCTION IN RATTHORACICAORTA
- Author
-
Uggeri, M. J., primary and Johns, R. A., additional
- Published
- 1990
- Full Text
- View/download PDF
7. Searching for Biomarkers of Aurora-A Kinase Activity: Identification of in Vitro Substrates through a Modified KESTREL Approach
- Author
-
Troiani, S., Uggeri, M., Moll, J., Isacchi, A., Kalisz, H. M., Rusconi, L., and Valsasina, B.
- Abstract
Aurora-A, -B, and -C are members of a small family of mitotic serine/threonine kinases that regulate centrosome maturation, chromosome segregation, and cytokinesis. They are often overexpressed in different human tumor types and have been identified as attractive targets for anticancer drug development. As specific inhibitors of the Aurora kinases are entering phase I clinical trials, there is a high need for appropriate Aurora-A biomarkers to follow mechanism of action or response. To identify novel Aurora-A substrates potentially useful as specific biomarkers we applied several modifications to the original KESTREL (Kinase Substrate Tracking and Elucidation) method in conjunction with gel electrophoresis and MALDI−MS and LC−MS/MS. The major modifications to the method included the introduction of a heating step to inactivate endogenous kinases after cell lysis and the execution of the in vitro kinase reaction in the presence of 5 mM Mg2+ and at high (1 mM) ATP concentration. Total and fractionated extracts from nocodazole-treated HeLa cells were used as a source of Aurora-A substrates. Using this approach, we were able to detect a number of Aurora-A specific phospholabeled signals and to identify vimentin as a putative Aurora-A substrate. Vimentin was then confirmed as an in vitro substrate of Aurora-A by the phosphorylation of the recombinant protein followed by MS and antibody detection. Keywords: aurora • substrate • phosphorylation • KESTREL • vimentin
- Published
- 2005
8. Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action
- Author
-
Beatrice Dalla Barba, Eugenio Baraldi, Chiara Zorloni, Silvia Azzena, Sara Schiavon, Nicoletta Masera, Paola Corti, Laura Sainati, Ursula Trafojer, Chiara Bergamo, Giuseppe Basso, Raffaella Colombatti, Andrea Biondi, Maddalena Martella, Michela Bracchi, Anita Cappellari, Paolo Emilio Tagliabue, Giampietro Viola, Marzia Uggeri, Laura Cattaneo, Colombatti, R, Martella, M, Cattaneo, L, Viola, G, Cappellari, A, Bergamo, C, Azzena, S, Schiavon, S, Baraldi, E, Dalla Barba, B, Trafojer, U, Corti, P, Uggeri, M, Tagliabue, P, Zorloni, C, Bracchi, M, Biondi, A, Basso, G, Masera, N, and Sainati, L
- Subjects
medicine.medical_specialty ,Pediatrics ,Population ,Prevalence ,Anemia, Sickle Cell ,Disease ,Italy ,newborn screening ,sickle cell disease ,Pediatrics, Perinatology and Child Health ,Hematology ,Oncology ,Infant, Newborn, Diseases ,03 medical and health sciences ,Neonatal Screening ,0302 clinical medicine ,Epidemiology ,Health care ,Humans ,Medicine ,education ,Newborn screening ,education.field_of_study ,business.industry ,Incidence ,Incidence (epidemiology) ,Infant, Newborn ,Hemoglobin variants ,Perinatology and Child Health ,Prognosis ,030220 oncology & carcinogenesis ,business ,030215 immunology - Abstract
Background: Sickle cell disease (SCD) is a chronic multisystem disorder requiring comprehensive care that includes newborn screening (NBS) as the first step of care. Italy still lacks a national SCD NBS program and policy on blood disorders. Pilot single-center screening programs and a regional targeted screening have been implemented so far, but more evidence is needed in order to impact health policies. Population and methods: NBS was offered to parents of newborns in gynecology clinics in Padova and Monza, tertiary care university hospitals in northern Italy. High-performance liquid chromatography (HPLC) was performed as the first test on samples collected on Guthrie cards. Molecular analysis of the beta-globin gene was performed on positive samples. Results: A total of 5466 newborns were enrolled; for 5439, informed consents were obtained. A similar family origin was seen in the two centers (65% Italians, 9% mixed couples, 26% immigrants). Compared with SCD NBS programs in the United States and Europe, our results show a similar incidence of SCD patients and carriers. All SCD patients had a Sub-Saharan family background; HbS carriers were 15% Caucasians (Italian, Albanians) and 10% from other areas (North Africa–India–South America); carriers of other hemoglobin variants were mainly (47%) from other areas. Conclusions: Our results demonstrate the feasibility of a multicentric NBS program for SCD, give information on HbS epidemiology in two Northern Italian Areas, and support previous European recommendation for a universal NBS program for SCD in Italy: a high incidence of patients and carriers has been detected, with a high percentage of Caucasian carriers, impossible to identify in a targeted NBS.
- Published
- 2019
9. Molecular Mechanisms Involved in the B Cell Growth and Clonogenic Activity of HIV-1 Matrix Protein p17 Variants.
- Author
-
D'Ursi P, Rondina A, Zani A, Uggeri M, Messali S, Caruso A, and Caccuri F
- Subjects
- Humans, HIV Infections virology, Cell Proliferation, Protein Folding, HIV Antigens genetics, HIV Antigens metabolism, HIV Antigens chemistry, HIV-1 genetics, HIV-1 physiology, B-Lymphocytes virology, gag Gene Products, Human Immunodeficiency Virus genetics, gag Gene Products, Human Immunodeficiency Virus metabolism, gag Gene Products, Human Immunodeficiency Virus chemistry
- Abstract
The human immunodeficiency virus (HIV-1) matrix protein p17 (p17) is released from infected cells as a protein capable of deregulating the biological activity of different cells. P17 variants (vp17s), more frequently detected in the plasma of HIV-1
+ patients with rather than without lymphoma and characterized by amino acids insertions in their C-terminal region, were found to trigger B cell growth and clonogenicity. Vp17s endowed with B-cell-growth-promoting activity are drastically destabilized, whereas, in a properly folded state, reference p17 (refp17) does not exert any biological activity on B cell growth and clonogenicity. However, misfolding of refp17 is necessary to expose a masked functional epitope, interacting with the protease-activated receptor 1 (PAR-1), endowed with B cell clonogenicity. Indeed, it is worth noting that changes in the secondary structure can strongly impact the function of a protein. Here, we performed computational studies to show that the gain of function of vp17s is linked to dramatic conformational changes due to structural modification in the secondary-structure elements and in the rearrangement of the hydrogen bond (H-bond) network. In particular, all clonogenic vp17s showed the disengagement of two critical residues, namely Trp16 and Tyr29, from their hydrophobic core. Biological data showed that the mutation of Trp16 and Tyr29 to Ala in the refp17 backbone, alone or in combination, resulted in a protein endowed with B cell clonogenic activity. These data show the pivotal role of the hydrophobic component in maintaining refp17 stability and identify a novel potential therapeutic target to counteract vp17-driven lymphomagenesis in HIV-1+ patients.- Published
- 2024
- Full Text
- View/download PDF
10. Molecular mechanisms behind the generation of pro-oncogenic HIV-1 matrix protein p17 variants.
- Author
-
Zani A, Messali S, Bugatti A, Uggeri M, Rondina A, Sclavi L, Caccuri F, and Caruso A
- Subjects
- Mutation, Genetic Variation, Cell Line, Tumor, Humans, Sequence Alignment, HIV Antigens genetics, gag Gene Products, Human Immunodeficiency Virus genetics, Oncogene Proteins genetics, Recombination, Genetic, HIV-1 genetics
- Abstract
HIV-1 matrix protein p17 variants (vp17s), characterized by amino acid insertions at the COOH-terminal region of the viral protein, have been recently identified and studied for their biological activity. Different from their wild-type counterpart (refp17), vp17s display a potent B cell growth and clonogenic activity. Recent data have highlighted the higher prevalence of vp17s in people living with HIV-1 (PLWH) with lymphoma compared with those without lymphoma, suggesting that vp17s may play a key role in lymphomagenesis. Molecular mechanisms involved in vp17 development are still unknown. Here we assessed the efficiency of HIV-1 Reverse Transcriptase (RT) in processing this genomic region and highlighted the existence of hot spots of mutation in Gag , at the end of the matrix protein and close to the matrix-capsid junction. This is possibly due to the presence of inverted repeats and palindromic sequences together with a high content of Adenine in the 322-342 nucleotide portion, which constrain HIV-1 RT to pause on the template. To define the recombinogenic properties of hot spots of mutation in the matrix gene, we developed plasmid vectors expressing Gag and a minimally modified Gag variant, and measured homologous recombination following cell co-nucleofection by next-generation sequencing. Data obtained allowed us to show that a wide range of recombination events occur in concomitance with the identified hot spots of mutation and that imperfect events may account for vp17s generation.
- Published
- 2024
- Full Text
- View/download PDF
11. Detection of HIV-1 matrix protein p17 in sera of viremic and aviremic patients.
- Author
-
Zani A, Messali S, Uggeri M, Bonfanti C, Caruso A, and Caccuri F
- Subjects
- Humans, gag Gene Products, Human Immunodeficiency Virus metabolism, HIV Antigens metabolism, Viremia, HIV-1, HIV Infections
- Abstract
People living with human immunodeficiency virus type 1 (HIV-1), even if successfully treated with a combined antiretroviral therapy, display a persistent inflammation and chronic immune activation, and an increasing risk of developing cardiovascular and thrombotic events, cancers, and neurologic disorders. Accumulating evidence reveals that biologically active HIV-1 proteins may play a role in the development of these HIV-1-associated conditions. The HIV-1 matrix protein p17 (p17) is released and accumulates in different organs and tissue where it may exert multiple biological activities on different target cells. To assess a role of p17 in different HIV-1-related pathological processes, it is central to definitively ascertain and quantitate its expression in a large number of sera obtained from HIV-1-infected (HIV-1
+ ) patients. To this aim, we developed a specific and highly sensitive p17 capture immunoenzymatic assay. Data obtained highlight a heterogeneous expression of p17 in blood of tested patients, with patients who were negative or displayed from low to relatively high p17 blood concentrations (range from 0.05 to 7.29 nM). Moreover, we found that blood p17 concentration was totally independent from the viremic status of the patient. This finding calls for monitoring HIV-1+ patients in order to evaluate a possible correlation between p17 amount in blood and the likelihood of developing HIV-1-related pathological conditions., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF
12. Germline NUP98 Variants in Two Siblings with a Rothmund-Thomson-Like Spectrum: Protein Functional Changes Predicted by Molecular Modeling.
- Author
-
Colombo EA, Valiante M, Uggeri M, Orro A, Majore S, Grammatico P, Gentilini D, Finelli P, Gervasini C, D'Ursi P, and Larizza L
- Subjects
- Humans, Siblings, Male, Female, Protein Conformation, Nuclear Pore Complex Proteins chemistry, Nuclear Pore Complex Proteins genetics, Rothmund-Thomson Syndrome genetics, Germ-Line Mutation
- Abstract
Two adult siblings born to first-cousin parents presented a clinical phenotype reminiscent of Rothmund-Thomson syndrome (RTS), implying fragile hair, absent eyelashes/eyebrows, bilateral cataracts, mottled pigmentation, dental decay, hypogonadism, and osteoporosis. As the clinical suspicion was not supported by the sequencing of RECQL4 , the RTS2-causative gene, whole exome sequencing was applied and disclosed the homozygous variants c.83G>A (p.Gly28Asp) and c.2624A>C (p.Glu875Ala) in the nucleoporin 98 ( NUP98 ) gene. Though both variants affect highly conserved amino acids, the c.83G>A looked more intriguing due to its higher pathogenicity score and location of the replaced amino acid between phenylalanine-glycine (FG) repeats within the first NUP98 intrinsically disordered region. Molecular modeling studies of the mutated NUP98 FG domain evidenced a dispersion of the intramolecular cohesion elements and a more elongated conformational state compared to the wild type. This different dynamic behavior may affect the NUP98 functions as the minor plasticity of the mutated FG domain undermines its role as a multi-docking station for RNA and proteins, and the impaired folding can lead to the weakening or the loss of specific interactions. The clinical overlap of NUP98 -mutated and RTS2/RTS1 patients, accounted by converging dysregulated gene networks, supports this first-described constitutional NUP98 disorder, expanding the well-known role of NUP98 in cancer.
- Published
- 2023
- Full Text
- View/download PDF
13. Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing.
- Author
-
Fossa P, Uggeri M, Orro A, Urbinati C, Rondina A, Milanesi M, Pedemonte N, Pesce E, Padoan R, Ford RC, Meng X, Rusnati M, and D'Ursi P
- Subjects
- Humans, Drug Repositioning, Proteasome Endopeptidase Complex metabolism, Benzodioxoles pharmacology, Benzodioxoles therapeutic use, Aminopyridines pharmacology, Aminopyridines therapeutic use, Niacinamide therapeutic use, Ubiquitins metabolism, Mutation, Cystic Fibrosis Transmembrane Conductance Regulator metabolism, Cystic Fibrosis drug therapy, Cystic Fibrosis genetics, Cystic Fibrosis metabolism
- Abstract
Cystic fibrosis is a hereditary disease mainly caused by the deletion of the Phe 508 (F508del) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is thus withheld in the endoplasmic reticulum and rapidly degraded by the ubiquitin/proteasome system. Cystic fibrosis remains a potentially fatal disease, but it has become treatable as a chronic condition due to some CFTR-rescuing drugs that, when used in combination, increase in their therapeutic effect due to a synergic action. Also, dietary supplementation of natural compounds in combination with approved drugs could represent a promising strategy to further alleviate cystic fibrosis symptoms. On these bases, we screened by in silico drug repositioning 846 small synthetic or natural compounds from the AIFA database to evaluate their capacity to interact with the highly druggable lumacaftor binding site of F508del-CFTR. Among the identified hits, nicotinamide (NAM) was predicted to accommodate into the lumacaftor binding region of F508del-CFTR without competing against the drug but rather stabilizing its binding. The effective capacity of NAM to bind F508del-CFTR in a lumacaftor-uncompetitive manner was then validated experimentally by surface plasmon resonance analysis. Finally, the capacity of NAM to synergize with lumacaftor increasing its CFTR-rescuing activity was demonstrated in cell-based assays. This study suggests the possible identification of natural small molecules devoid of side effects and endowed with the capacity to synergize with drugs currently employed for the treatment of cystic fibrosis, which hopefully will increase the therapeutic efficacy with lower doses.
- Published
- 2022
- Full Text
- View/download PDF
14. In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library.
- Author
-
Orro A, Uggeri M, Rusnati M, Urbinati C, Pedemonte N, Pesce E, Moscatelli M, Padoan R, Cichero E, Fossa P, and D'Ursi P
- Subjects
- Cystic Fibrosis Transmembrane Conductance Regulator metabolism, Datasets as Topic, Dose-Response Relationship, Drug, Drug Repositioning, Humans, Molecular Structure, Phenylalanine metabolism, Small Molecule Libraries chemistry, Structure-Activity Relationship, Cystic Fibrosis Transmembrane Conductance Regulator antagonists & inhibitors, Phenylalanine antagonists & inhibitors, Small Molecule Libraries pharmacology
- Abstract
Computational drug repositioning is of growing interest to academia and industry, for its ability to rapidly screen a huge number of candidates in silico (exploiting comprehensive drug datasets) together with reduced development cost and time. The potential of drug repositioning has not been fully evaluated yet for cystic fibrosis (CF), a disease mainly caused by deletion of Phe 508 (F508del) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. F508del-CFTR is thus withheld in the endoplasmic reticulum and rapidly degraded by the ubiquitin/proteasome system. CF is still a fatal disease. Nowadays, it is treatable by some CFTR-rescuing drugs, but new-generation drugs with stronger therapeutic benefits and fewer side effects are still awaited. In this manuscript we report about the results of a pilot computational drug repositioning screening in search of F508del-CFTR-targeted drugs performed on AIFA library by means of a dedicated computational pipeline and surface plasmon resonance binding assay to experimentally validate the computational findings., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
15. Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin.
- Author
-
Caccuri F, D'Ursi P, Uggeri M, Bugatti A, Mazzuca P, Zani A, Filippini F, Salmona M, Ribatti D, Slevin M, Orro A, Lu W, Liò P, Gallo RC, and Caruso A
- Subjects
- Cells, Cultured, Epitopes immunology, Erythropoietin metabolism, Evolution, Molecular, HIV Antigens genetics, HIV Seropositivity, HIV-1 genetics, HIV-2, Humans, Molecular Mimicry, Simian Immunodeficiency Virus, gag Gene Products, Human Immunodeficiency Virus genetics, Erythropoietin genetics, HIV Antigens metabolism, HIV-1 metabolism, gag Gene Products, Human Immunodeficiency Virus metabolism
- Abstract
The HIV-1 matrix protein p17 (p17) is a pleiotropic molecule impacting on different cell types. Its interaction with many cellular proteins underlines the importance of the viral protein as a major determinant of human specific adaptation. We previously showed the proangiogenic capability of p17. Here, by integrating functional analysis and receptor binding, we identify a functional epitope that displays molecular mimicry with human erythropoietin (EPO) and promotes angiogenesis through common beta chain receptor (βCR) activation. The functional EPO-like epitope was found to be present in the matrix protein of HIV-1 ancestors SIV originated in chimpanzees (SIVcpz) and gorillas (SIVgor) but not in that of HIV-2 and its ancestor SIVsmm from sooty mangabeys. According to biological data, evolution of the EPO-like epitope showed a clear differentiation between HIV-1/SIVcpz-gor and HIV-2/SIVsmm branches, thus highlighting this epitope on p17 as a divergent signature discriminating HIV-1 and HIV-2 ancestors. P17 is known to enhance HIV-1 replication. Similarly to other βCR ligands, p17 is capable of attracting and activating HIV-1 target cells and promoting a proinflammatory microenvironment. Thus, it is tempting to speculate that acquisition of an epitope on the matrix proteins of HIV-1 ancestors capable of triggering βCR may have represented a critical step to enhance viral aggressiveness and early human-to-human SIVcpz/gor dissemination. The hypothesis that the p17/βCR interaction and βCR abnormal stimulation may also play a role in sustaining chronic activation and inflammation, thus marking the difference between HIV-1 and HIV-2 in term of pathogenicity, needs further investigation., Competing Interests: Competing interest statement: F.C. and A.C. are listed as inventors in a patent application related to this study., (Copyright © 2021 the Author(s). Published by PNAS.)
- Published
- 2021
- Full Text
- View/download PDF
16. Recent Strategic Advances in CFTR Drug Discovery: An Overview.
- Author
-
Rusnati M, D'Ursi P, Pedemonte N, Urbinati C, Ford RC, Cichero E, Uggeri M, Orro A, and Fossa P
- Subjects
- Biosensing Techniques, Computational Biology, Cystic Fibrosis drug therapy, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Humans, Models, Molecular, Protein Conformation, Cystic Fibrosis Transmembrane Conductance Regulator chemistry, Cystic Fibrosis Transmembrane Conductance Regulator drug effects, Drug Discovery methods
- Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR)-rescuing drugs have already transformed cystic fibrosis (CF) from a fatal disease to a treatable chronic condition. However, new-generation drugs able to bind CFTR with higher specificity/affinity and to exert stronger therapeutic benefits and fewer side effects are still awaited. Computational methods and biosensors have become indispensable tools in the process of drug discovery for many important human pathologies. Instead, they have been used only piecemeal in CF so far, calling for their appropriate integration with well-tried CF biochemical and cell-based models to speed up the discovery of new CFTR-rescuing drugs. This review will give an overview of the available structures and computational models of CFTR and of the biosensors, biochemical and cell-based assays already used in CF-oriented studies. It will also give the reader some insights about how to integrate these tools as to improve the efficiency of the drug discovery process targeted to CFTR.
- Published
- 2020
- Full Text
- View/download PDF
17. Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications.
- Author
-
Bugatti A, Paiardi G, Urbinati C, Chiodelli P, Orro A, Uggeri M, Milanesi L, Caruso A, Caccuri F, D'Ursi P, and Rusnati M
- Subjects
- Cell Line, Tumor, Heparin chemistry, Heparin metabolism, Humans, Acquired Immunodeficiency Syndrome metabolism, HIV Antigens chemistry, HIV Antigens metabolism, HIV-1 chemistry, HIV-1 metabolism, MAP Kinase Signaling System, Protein Multimerization, Syndecan-1 chemistry, Syndecan-1 metabolism, gag Gene Products, Human Immunodeficiency Virus chemistry, gag Gene Products, Human Immunodeficiency Virus metabolism
- Abstract
p17 matrix protein released by HIV+ cells interacts with leukocytes heparan sulfate proteoglycans (HSPGs), CXCR1 and CXCR2 exerting different cytokine-like activities that contribute to AIDS pathogenesis. Since the bioactive form of several cytokines is represented by dimers/oligomers and oligomerization is promoted by binding to heparin or HSPGs, here we evaluated if heparin/HSPGs also promote p17 oligomerization. Heparin favours p17 dimer, trimer and tetramer assembly, in a time- and biphasic dose-dependent way. Heparin-induced p17 oligomerization is of electrostatic nature, being it prevented by NaCl, by removing negative sulfated groups of heparin and by neutralizing positive lysine residues in the p17 N-terminus. A new computational protocol has been implemented to study heparin chains up to 24-mer accommodating a p17 dimer. Molecular dynamics show that, in the presence of heparin, two p17 molecules undergo conformational modifications creating a continuous "electropositive channel" in which heparin sulfated groups interact with p17 basic amino acids, promoting its dimerization. At the cell surface, HSPGs induce p17 oligomerization, as demonstrated by using B-lymphoblastoid Namalwa cells overexpressing the HSPG Syndecan-1. Also, HSPGs on the surface of BJAB and Raji human B-lymphoblastoid cells are required to p17 to induce ERK
1/2 activation, suggesting that HS-induced oligomerization plays a role in p17-induced lymphoid dysregulation during AIDS.- Published
- 2019
- Full Text
- View/download PDF
18. Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action.
- Author
-
Colombatti R, Martella M, Cattaneo L, Viola G, Cappellari A, Bergamo C, Azzena S, Schiavon S, Baraldi E, Dalla Barba B, Trafojer U, Corti P, Uggeri M, Tagliabue PE, Zorloni C, Bracchi M, Biondi A, Basso G, Masera N, and Sainati L
- Subjects
- Humans, Incidence, Infant, Newborn, Italy epidemiology, Prognosis, Anemia, Sickle Cell diagnosis, Anemia, Sickle Cell epidemiology, Infant, Newborn, Diseases diagnosis, Infant, Newborn, Diseases epidemiology, Neonatal Screening methods
- Abstract
Background: Sickle cell disease (SCD) is a chronic multisystem disorder requiring comprehensive care that includes newborn screening (NBS) as the first step of care. Italy still lacks a national SCD NBS program and policy on blood disorders. Pilot single-center screening programs and a regional targeted screening have been implemented so far, but more evidence is needed in order to impact health policies., Population and Methods: NBS was offered to parents of newborns in gynecology clinics in Padova and Monza, tertiary care university hospitals in northern Italy. High-performance liquid chromatography (HPLC) was performed as the first test on samples collected on Guthrie cards. Molecular analysis of the beta-globin gene was performed on positive samples., Results: A total of 5466 newborns were enrolled; for 5439, informed consents were obtained. A similar family origin was seen in the two centers (65% Italians, 9% mixed couples, 26% immigrants). Compared with SCD NBS programs in the United States and Europe, our results show a similar incidence of SCD patients and carriers. All SCD patients had a Sub-Saharan family background; HbS carriers were 15% Caucasians (Italian, Albanians) and 10% from other areas (North Africa-India-South America); carriers of other hemoglobin variants were mainly (47%) from other areas., Conclusions: Our results demonstrate the feasibility of a multicentric NBS program for SCD, give information on HbS epidemiology in two Northern Italian Areas, and support previous European recommendation for a universal NBS program for SCD in Italy: a high incidence of patients and carriers has been detected, with a high percentage of Caucasian carriers, impossible to identify in a targeted NBS., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
19. Inhibitor affinity chromatography: profiling the specific reactivity of the proteome with immobilized molecules.
- Author
-
Lolli G, Thaler F, Valsasina B, Roletto F, Knapp S, Uggeri M, Bachi A, Matafora V, Storici P, Stewart A, Kalisz HM, and Isacchi A
- Subjects
- Animals, Blotting, Western, CDC2-CDC28 Kinases antagonists & inhibitors, Calorimetry, Cell Line, Cell Line, Tumor, Cyclin A metabolism, Cyclin-Dependent Kinase 2, Dose-Response Relationship, Drug, Electrophoresis, Polyacrylamide Gel, HSP27 Heat-Shock Proteins, HSP70 Heat-Shock Proteins metabolism, Heat-Shock Proteins metabolism, Humans, Insecta, Ligands, Mass Spectrometry, Models, Chemical, Molecular Chaperones, Neoplasm Proteins metabolism, Polymers chemistry, Protein Binding, Proteome, Rats, Spectrometry, Fluorescence, Thermodynamics, Trypsin pharmacology, Chromatography methods, Electrophoresis, Gel, Two-Dimensional methods
- Abstract
An inhibitor affinity chromatography (IAC) method has been developed for the analysis of inhibitor-protein interactions as a complementary approach to two-dimensional electrophoresis for functional proteomics studies. The procedure was developed utilizing a cyclin-dependent kinase 2 (Cdk2) inhibitor coupled to a polymeric resin and validated using a number of proteins interacting with the inhibitor with different specificities. Cdk2 and the other kinases bound and eluted from the resin in accordance with the relative in vitro potency of the inhibitor for each enzyme. Molecular interactions with the Cdk2 inhibitor were compared for HCT116 cancer cells versus rat pancreatic acinar cells. Proteins interacting with the ligand on the IAC matrix were identified by mass spectrometry. Isothermal calorimetry was used to confirm and quantitatively evaluate the binding affinity of some of the interacting proteins. Heat-shock protein (Hsp) 70 and Hsp27 were the strongest interactors with the inhibitor, displaying binding affinities comparable to those of Cdk2. These results support the use of IAC as a general method for the rapid identification and qualitative evaluation of the in vivo targets and potential side effects of a given drug.
- Published
- 2003
- Full Text
- View/download PDF
20. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.
- Author
-
Bongarzone I, Vigano E, Alberti L, Mondellini P, Uggeri M, Pasini B, Borrello MG, and Pierotti MA
- Subjects
- 3T3 Cells drug effects, Animals, Cell Membrane metabolism, Cell Transformation, Neoplastic drug effects, Dimerization, Endoplasmic Reticulum metabolism, Glutamic Acid, Leucine, Mercaptoethanol pharmacology, Mice, Phosphorylation, Polysaccharides metabolism, Precipitin Tests, Protein Precursors metabolism, Protein Processing, Post-Translational, Proteins metabolism, Proto-Oncogene Proteins drug effects, Proto-Oncogene Proteins c-ret, Receptor Protein-Tyrosine Kinases drug effects, Shc Signaling Adaptor Proteins, Signal Transduction, Src Homology 2 Domain-Containing, Transforming Protein 1, Adaptor Proteins, Signal Transducing, Adaptor Proteins, Vesicular Transport, Cysteine metabolism, Drosophila Proteins, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, Receptor Protein-Tyrosine Kinases genetics, Receptor Protein-Tyrosine Kinases metabolism, Sequence Deletion
- Abstract
Mutations of the RET gene, encoding a receptor tyrosine kinase, have been associated with the inherited cancer syndromes MEN 2A and MEN 2B. They have also further been associated with both familial and sporadic medullary thyroid carcinomas. Missense mutations affecting cysteine residues within the extracellular domain of the receptor causes constitutive tyrosine kinase activation through the formation of disulfide-bonded homodimers. We have recently reported that a somatic 6 bp in-frame deletion, originally coding for Glu632-Leu633, potently activates the RET gene. This activation is increased with respect to the frequent MEN 2A-associated missense mutation Cys634Arg. This finding specifically correlated to the clinic behavior of the corresponding tumor, which was characterized by an unusually aggressive progression with both multiple and recurrent metastases. By examining the possibility that this deletion acts in a manner similar to cysteine substitution, we have analysed the molecular mechanism by which this oncogenic activation occurs. Phosphorylated dimers of the deleted Ret receptor were detected in immunoprecipitates separated under non-reducing conditions. Like other Cys point mutations, this 6 bp deletion affecting two amino acid residues between two adjacent Cys, is capable of activating the transforming ability of Ret by promoting receptor dimerization. These results suggest that alteration to cysteine residue position or pairing is capable of inducing ligand independent dimerization. Furthermore, we present data demonstrating that the processing and sorting of the Ret membrane receptor to the cell surface is affected by mutation type.
- Published
- 1999
- Full Text
- View/download PDF
21. [Principles of a rehabilitation treatment for returning to work after a stabilization intervention with the Colorado method].
- Author
-
Selletti L, Taveggia G, Grioni G, Uggeri M, Loda M, and Pastorelli GM
- Subjects
- Adult, Aged, Arthrodesis methods, Female, Humans, Male, Middle Aged, Occupational Diseases surgery, Spondylolisthesis surgery, Lumbar Vertebrae surgery, Occupational Diseases rehabilitation, Program Evaluation, Spondylolisthesis rehabilitation
- Abstract
The Authors report their experience on the method of Colorado Spinal System for reduction in spondylolisthesis; they describe a postoperative rehabilitative programme for a complete and quick functional recovery. They eventually report the clinical results achieved in 15 patients.
- Published
- 1997
22. Halothane, enflurane, and isoflurane attenuate both receptor- and non-receptor-mediated EDRF production in rat thoracic aorta.
- Author
-
Uggeri MJ, Proctor GJ, and Johns RA
- Subjects
- Animals, Aorta, Thoracic metabolism, Calcimycin pharmacology, Depression, Chemical, In Vitro Techniques, Male, Methacholine Chloride pharmacology, Nitroprusside pharmacology, Rats, Rats, Inbred Strains, Aorta, Thoracic drug effects, Enflurane pharmacology, Halothane pharmacology, Isoflurane pharmacology, Nitric Oxide biosynthesis
- Abstract
EDRF (endothelium-derived relaxing factor) is a cellular and intercellular messenger that activates soluble guanylate cyclase. In blood vessels it is released from the endothelium and causes relaxation of vascular smooth muscle. Halothane previously has been shown to attenuate EDRF-induced vasodilation elicited by the receptor-mediated vasodilators acetylcholine and bradykinin and to alter muscarinic receptor activity. We examined and compared the effects of the inhaled anesthetics halothane, enflurane, and isoflurane on endothelium-dependent vasodilation and tested the hypothesis that these agents inhibit EDRF-mediated vasodilation solely through inhibition of endothelial cell receptor-mediated EDRF release. Isolated rat thoracic aortic rings were mounted for isometric tension recording and preconstricted with phenylephrine. Cumulative dose-response curves were obtained to methacholine, a receptor-mediated endothelium-dependent dilator; to A23187, a nonreceptor-mediated endothelium-dependent dilator; and to sodium nitroprusside, a direct-acting endothelium-independent dilator before, during, and after inhalational anesthetic exposure. Both receptor-mediated and non-receptor-mediated endothelium-dependent relaxation by methacholine and A23187, respectively, were significantly (P less than 0.01 to P less than 0.05) and reversibly attenuated by halothane, enflurane, and isoflurane at 2 MAC and by isoflurane at 1 MAC. Endothelium-independent relaxation by sodium nitroprusside, an agent that acts directly on the vascular smooth muscle cell to activate guanylate cyclase, was unaffected by any of the anesthetics at any concentration tested. Indomethacin had no significant effect on the inhibition of endothelium-dependent vasodilation by these inhalational anesthetics. We conclude that halothane, enflurane, and isoflurane inhibit endothelium-dependent vasodilation; that isoflurane is more potent than halothane and enflurane in this regard.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF
23. [Piezo-ceramic lithotripsy applied to calculi of the bile ducts. Experiences with 45 patients].
- Author
-
Uggeri M
- Subjects
- Adult, Aged, Bile Duct Diseases therapy, Evaluation Studies as Topic, Female, Humans, Male, Middle Aged, Cholelithiasis therapy, Lithotripsy instrumentation
- Abstract
Forty five patients with gallbladder stones has been treated by extracorporeal lithotripsy with piezoceramic lithotripter. The efficacy, the safety and the side effects of the treatment had been evaluated. In 40 patients the stone was completely broken, 35 patients needed more than a single treatment (1 to 5). All the treatments were carried out in local anesthesia without any analgesia drug. No one patients complained for any pain. The side effects recorded were 3 cases of microscopic hematuria, 2 cases slight increase of serum parameters of hepatic functionality, in 7 cases skin petecchiae. No mayor effects were noted.
- Published
- 1989
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.